Hiperkolesterolemia Familial

01Pathophysiology

Understanding familial dyslipidemias requires a firm grasp of the lipoprotein metabolism pathway. Each type represents a breakdown at a different point in this pathway, and the exam tests whether you can connect the molecular defect to the clinical phenotype.

Normal lipoprotein metabolism in brief: Dietary fat is packaged into chylomicrons by the intestine. In the capillary beds, lipoprotein lipase (LPL) hydrolyzes the triglycerides in chylomicrons and VLDL, releasing free fatty acids to tissues. LPL requires ApoC-II as a cofactor. After triglyceride removal, chylomicrons become chylomicron remnants, which are cleared by the liver via ApoE-mediated receptor binding. The liver independently produces VLDL, which undergoes the same LPL-mediated lipolysis to become IDL, and then LDL. LDL is cleared from the circulation by hepatic LDL receptors that recognize ApoB-100.

Type I (Familial Chylomicronemia): The defect is at the very first step of triglyceride processing. Either LPL itself is absent or dysfunctional, or its essential cofactor ApoC-II is deficient. Without LPL activity, chylomicrons cannot be broken down and accumulate in the plasma. This is why the serum turns grossly lipemic and, when refrigerated overnight, forms a creamy supernatant (chylomicrons float because of their low density). The severe hypertriglyceridemia causes eruptive xanthomas (triglyceride-laden macrophages deposited in the skin) and places the patient at high risk for acute pancreatitis from direct fatty acid toxicity to pancreatic acinar cells. Critically, because the LDL pathway is unaffected, these patients do not develop premature atherosclerosis. The disease presents in childhood, which is unusual for lipid disorders and should immediately raise suspicion.

Type IIa (Familial Hypercholesterolemia, FH): This is the highest-yield familial dyslipidemia on exams. The defect involves the LDL receptor on hepatocytes. More than 1600 mutations have been described, but they all lead to the same outcome: impaired clearance of LDL from the blood. In heterozygous FH, the patient has one functional copy, LDL levels are roughly 2x normal (typically 300-400 mg/dL), and they develop premature ASCVD in their 30s to 50s. In homozygous FH, both copies are defective, LDL levels reach 600-1000+ mg/dL, and patients can suffer MI before age 20. The pathophysiology directly explains the physical exam findings: sustained LDL elevation leads to cholesterol deposition in tendons (tendon xanthomas, especially the Achilles tendon and hand extensor tendons), in the periorbital skin (xanthelasma), and at the corneal periphery (corneal arcus). Tendon xanthomas are considered virtually pathognomonic for FH and should never be dismissed as a background finding in a vignette.

Type IIb (Familial Combined Hyperlipidemia, FCH): This is the most common inherited lipid disorder, affecting roughly 1-2% of the population. The defect is hepatic overproduction of ApoB-100, leading to excess secretion of both VLDL and LDL. The key conceptual point is that this disorder has a variable phenotype, even within the same family: one member might show isolated hypercholesterolemia, another might show isolated hypertriglyceridemia, and a third might show both. This phenotypic variability distinguishes it from FH (where LDL is consistently and markedly elevated). These patients develop premature ASCVD but lack the dramatic physical exam findings seen in FH.

Type III (Familial Dysbetalipoproteinemia): The defect is in ApoE, the ligand that mediates hepatic uptake of chylomicron remnants and IDL. Patients are homozygous for the ApoE2 allele, which binds poorly to hepatic remnant receptors. However, ApoE2/E2 homozygosity alone is usually not sufficient to cause disease. A second metabolic hit (obesity, diabetes mellitus, hypothyroidism, or estrogen deficiency) is typically required to unmask the phenotype. The accumulated IDL particles (also called beta-VLDL) are both cholesterol-rich and triglyceride-rich, producing a characteristic pattern of roughly equal elevation of cholesterol and triglycerides. These abnormal remnant particles are highly atherogenic and are taken up by macrophages in unusual locations, producing palmar xanthomas (yellowish deposits in the palmar creases), which are pathognomonic for this disease. Tuberoeruptive xanthomas over the elbows and knees are also common.

Type IV (Familial Hypertriglyceridemia): The defect is hepatic overproduction of VLDL, resulting in isolated elevation of triglycerides while LDL remains normal. The underlying mechanism is not fully characterized but involves increased hepatic lipogenesis. The clinical significance depends on the degree of elevation: moderate hypertriglyceridemia (250-500) carries a modest increase in ASCVD risk, while severe elevation (>1000) places the patient at risk for pancreatitis. This disorder is strongly modulated by secondary factors such as alcohol intake, uncontrolled diabetes, obesity, and estrogen use. In a vignette, expect a patient with hypertriglyceridemia where the history reveals heavy alcohol use or poorly controlled diabetes as a precipitant.

Type V: This represents a combination of Type I and Type IV physiology. There is both VLDL overproduction and impaired chylomicron clearance, resulting in elevation of both particle types. On refrigerated serum, this produces the classic finding of a creamy supernatant (chylomicrons) overlying a turbid infranatant (excess VLDL). The clinical picture combines features of both: pancreatitis risk from extreme hypertriglyceridemia plus modest ASCVD risk. It typically presents in adulthood, unlike Type I which presents in childhood.

02Classification and Clinical Manifestation

Fredrickson-Levy-Lees Classification

Xanthoma Types by Disease

03Diagnostic Workup

The workup begins with a fasting lipid panel in every case. The pattern of abnormalities is the first branch point:

For isolated severe hypercholesterolemia (LDL >190 in an adult, >160 in a child) with normal triglycerides, the working diagnosis is Type IIa (FH). The best initial diagnostic step in a clinical vignette is applying the Dutch Lipid Clinic Network Score or Simon Broome criteria, which integrate LDL level, physical findings (tendon xanthomas), family history of premature ASCVD, and genetic testing. Genetic testing for LDLR, ApoB, or PCSK9 gain-of-function mutations is the most accurate confirmatory test. However, a clinical diagnosis of FH can be made without genetic confirmation if the LDL is >190, tendon xanthomas are present, and there is a first-degree relative with premature coronary disease. The exam frequently uses the "LDL >190 with tendon xanthomas in a young patient" combination as the clinical trigger.

For isolated severe hypertriglyceridemia (TG >1000) in a child, think Type I. The refrigerated serum test (leaving the sample overnight at 4 degrees Celsius) is the best initial discriminating test: a creamy supernatant with a clear infranatant confirms chylomicron excess. The most accurate test is a post-heparin LPL activity assay, where heparin releases LPL from the endothelial surface and its activity is measured directly. Absent or near-absent activity confirms the diagnosis. If LPL activity is normal, measure ApoC-II levels to evaluate for cofactor deficiency.

For combined hypercholesterolemia and hypertriglyceridemia with roughly equal elevation of both, suspect Type III. The best initial clue is the lipid pattern itself combined with palmar xanthomas. The confirmatory test is lipoprotein electrophoresis, which demonstrates a characteristic broad beta band representing the abnormal IDL particles that migrate between the pre-beta (VLDL) and beta (LDL) positions. ApoE genotyping showing homozygous E2/E2 provides definitive genetic confirmation. An important point: the standard Friedewald equation for calculating LDL is unreliable in Type III because it assumes a fixed VLDL cholesterol-to-triglyceride ratio, which does not hold when IDL is accumulating.

For isolated hypertriglyceridemia (TG 250-1000) in an adult, consider Type IV after ruling out secondary causes. The refrigerated serum test shows a uniformly turbid sample without a creamy supernatant (excess VLDL distributes evenly rather than floating). The critical workup step here is to exclude secondary causes: poorly controlled diabetes, hypothyroidism, alcohol excess, medications (thiazides, beta-blockers, estrogens, retinoids, protease inhibitors). If TG remains elevated after addressing secondary causes, the diagnosis of familial hypertriglyceridemia is supported.

For severe hypertriglyceridemia (TG >1000) in an adult presenting with features of both chylomicronemia and VLDL excess, consider Type V. The refrigerated serum test shows a creamy supernatant plus a turbid infranatant, distinguishing it from Type I (clear infranatant) and Type IV (no supernatant).

04Management and Treatment

Management of Type IIa (FH) deserves the most detailed discussion because it is the most commonly tested.

For heterozygous FH, the cornerstone is a high-intensity statin. Atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily should be initiated at the time of diagnosis, regardless of age (treatment begins in childhood for FH, typically at age 8-10). The goal is at least a 50% reduction in LDL from baseline. If the target is not reached with maximal statin therapy, add ezetimibe 10 mg daily, which blocks intestinal cholesterol absorption via the NPC1L1 transporter and provides an additional 15-20% LDL reduction. If LDL remains above goal despite statin + ezetimibe, PCSK9 inhibitors are indicated. Evolocumab (140 mg subcutaneously every 2 weeks) and alirocumab (75 mg subcutaneously every 2 weeks, up-titrated to 150 mg) work by preventing degradation of LDL receptors on the hepatocyte surface, thereby increasing LDL clearance. These agents can lower LDL by an additional 50-60%.

For homozygous FH, standard pharmacotherapy is often insufficient because there are few or no functional LDL receptors for PCSK9 inhibitors to upregulate. These patients typically require LDL apheresis (an extracorporeal procedure that physically removes LDL particles from the blood) performed every 1-2 weeks. Lomitapide (a microsomal triglyceride transfer protein inhibitor, 5-60 mg daily) reduces hepatic VLDL production and consequently LDL formation, but carries a risk of hepatic steatosis and requires monitoring of liver enzymes. Evinacumab (anti-ANGPTL3 monoclonal antibody, 15 mg/kg IV monthly) is a newer agent that lowers LDL through an LDL-receptor-independent pathway, making it effective even in receptor-negative homozygous FH. Liver transplantation is a last resort for receptor-negative patients unresponsive to all other therapies, as the transplanted liver provides functional LDL receptors.

For Type III, the management pearl is the dramatic response to fibrate therapy. Because the underlying defect is impaired remnant clearance (not production), fibrates, which activate PPAR-alpha and enhance LPL activity and remnant clearance, are exceptionally effective. Patients often see normalization of lipids within weeks. However, addressing the secondary metabolic trigger (weight loss for obesity, metformin for diabetes, levothyroxine for hypothyroidism) is equally important and may even resolve the dyslipidemia on its own.

For hypertriglyceridemia (Types IV, V, and the acute management of Type I), the immediate clinical priority depends on the TG level. When TG is >1000 mg/dL, the primary concern is pancreatitis prevention, and the approach centers on extreme fat restriction, IV fluids, and in severe cases, insulin infusion (which activates LPL and accelerates triglyceride clearance). Once the acute risk is mitigated, chronic management involves fibrates, omega-3 fatty acids (icosapent ethyl, which has demonstrated ASCVD benefit in the REDUCE-IT trial at 4g/day), and rigorous control of secondary factors. When TG is 500-1000, fibrate therapy is indicated. When TG is <500, lifestyle modification and statin therapy (for overall ASCVD risk) are generally sufficient, with the addition of icosapent ethyl if ASCVD risk is elevated.

Contraindications and drug interactions to remember: Gemfibrozil combined with statins substantially increases the risk of rhabdomyolysis (gemfibrozil inhibits statin glucuronidation). If a fibrate-statin combination is needed, fenofibrate is the safer choice. Statins are contraindicated in pregnancy (Category X) due to teratogenicity. Niacin can worsen glucose tolerance and precipitate gout (via hyperuricemia), making it a poor choice in diabetic or gout-prone patients.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common trap with familial dyslipidemia questions is failing to distinguish primary from secondary causes. A vignette might describe a patient with elevated LDL and then bury a TSH of 12 mU/L or a urine dipstick showing 4+ protein in the history. Students who jump straight to "familial hypercholesterolemia" without checking for hypothyroidism or nephrotic syndrome will select the wrong diagnosis. The exam tests whether you systematically exclude secondary causes before invoking a genetic disorder.

The second major trap involves Type III dysbetalipoproteinemia. Test-writers love this condition because it has two pathognomonic features that most students do not know: palmar xanthomas and the broad beta band on electrophoresis. A vignette describing yellow discoloration in the palmar creases of a middle-aged patient with combined hyperlipidemia is pointing directly at Type III, but students who are unfamiliar with palmar xanthomas will incorrectly select Type IIb.

A third trap is the management of homozygous FH. Students instinctively choose "high-dose statin" for any hypercholesterolemia question. However, in homozygous FH with complete absence of LDL receptors, statins have minimal effect because they work by upregulating LDL receptor expression on hepatocytes. The correct answer in a vignette describing a child with LDL >600 and a family history of childhood MI is LDL apheresis, not statins alone. PCSK9 inhibitors similarly have reduced efficacy in receptor-negative homozygous FH, which is why evinacumab (receptor-independent mechanism) was developed.

Fourth, the refrigerated serum test is a classic exam concept. Students should be able to match each pattern to the correct type: creamy top with clear bottom = Type I, uniformly turbid = Type IV, creamy top with turbid bottom = Type V. This simple test appears repeatedly in the question pool.

Finally, remember that Type I does not cause atherosclerosis. This is counterintuitive, since the lipid levels are severely abnormal. The reason is that chylomicrons are too large to penetrate the arterial intima. The atherogenic particles are LDL and IDL, not chylomicrons. A question asking about ASCVD risk in a child with recurrent pancreatitis and eruptive xanthomas is testing whether you know that the answer is "no increased atherosclerosis risk" despite the dramatic lipid panel.

The core competency being tested across all familial dyslipidemia questions is pattern recognition: linking the lipoprotein class elevated to the molecular defect, the physical exam findings, and the correct treatment. The Fredrickson classification is the organizing framework, and each type has at least one distinguishing feature that the exam expects you to recall instantly.